Reckitt Benckiser Group

Q2 2025: Strong core business drives outperformance

25/07/25 -"Reckitt reported Q2 2025 revenue of £3.3 billion, up 1.9% on a LFL basis with Core Reckitt up 5.3%, driven by strong performance in Emerging Markets(14.9%). This was partially offset by declines in ..."

PDF page sample
Pages
52
Language
English
Published on
25/07/25
Download
You may also be interested by these reports :
31/07/25
Haleon’s H1 profitability surpassed expectations. Sales growth was primarily driven by Oral Health, Therapeutic Skin Health, Pain Relief, and VMS, ...
31/07/25
Bic posted a mixed H1 FY25, with EBIT and EPS slightly ahead of expectations, but FCF missing significantly at -€14m. Sales declined 2.7% yoy in Q2, ...
31/07/25
The company exceeded expectations with organic growth of 3.4% vs anticipated 3.3%, bolstering market confidence in its strength and future ...
25/07/25
Reckitt reported Q2 2025 revenue of £3.3 billion, up 1.9% on a LFL basis with Core Reckitt up 5.3%, driven by strong performance in Emerging ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO